May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Effect of Brimonidine on Expression of Fibronectin and SMAD Signaling Pathway in Subconjuctival Fbroblasts Activated by TGF–ß
Author Affiliations & Notes
  • Y. Iizuka
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • K.S. Park
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • H.Y. Yeom
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • S.J. Ha
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • Y.J. Hong
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • G.J. Seong
    Ophthalmology, Institute of vision Research Yonsei University College of Medicine, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  Y. Iizuka, None; K.S. Park, None; H.Y. Yeom, None; S.J. Ha, None; Y.J. Hong, None; G.J. Seong, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 44. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Iizuka, K.S. Park, H.Y. Yeom, S.J. Ha, Y.J. Hong, G.J. Seong; Effect of Brimonidine on Expression of Fibronectin and SMAD Signaling Pathway in Subconjuctival Fbroblasts Activated by TGF–ß . Invest. Ophthalmol. Vis. Sci. 2006;47(13):44.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Transforming growth factor–ß (TGF–ß) have been shown to play a key role in wound healing after trabeculectomy and they use SMAD pathway for signaling. In this study we examine the effect of brimonidine, relative alpha 2 agonist, on expression of fibronectin and phospho SMAD in subconjuctival fibroblasts (SCFs) activated by TGF– ß.

Methods: : We stimulated the human cultured SCFs for 48hrs with various concentrations of TGF–ß and immunoblotted the stimulated cells with anti–fibronectin antibody. In order to determine whether TGF–ß–stimulated expression of fibronectin may be affected by brimonidine, SCFs treated with or without TGF–ß were cultured in the presence of various concentrations of brimonidine (10 nM, 100 nM, 1uM, 10 uM) and examined by western blot analysis. In order to know the effect of brimonidine on SMAD signaling pathway, SCFs stimulated with TGF–ß were cultured in the presence of brimonidine 100nM and immunoblotted the stimulated cells with anti–phospho SMAD antibody. Cell viability was detected by MTT assay.

Results: : SCFs expressed alpha 2 receptors. SCFs activated by TGF– ß enhanced the expression of fibronectin. Brimonidine reduced the expression of fibronectin in SCFs activated by TGF– ß. Brimonidine reduced the expression of phospho SMAD in early period. TGF– ß stimulated the proliferation of SCFs and brimonidine inhibited the proliferation of SCFs.

Conclusions: : These results may indicate that brimonidine inhibit the expression of fibronectin via reduction of phosphorylation of SMAD. Further study will be needed to find out the mechanism that brimonidine inhibit the phosphorylation of SMAD.

Keywords: wound healing • drug toxicity/drug effects • signal transduction: pharmacology/physiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×